Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma

LBA38_PRDABRAFENIB IN PATIENTS WITH BRAF V600E-MUTANT ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): A MULTICENTER, OPEN-LABEL, PHASE II TRIAL (BRF113928)

(2017) D. Planchard et al.   ANNALS OF ONCOLOGY

Crizotinib and Testing for ALK

(2017) Alice T. Shaw et al.   Journal of the National Comprehensive Cancer Network

Routine Clinical Mutation Profiling of Non–Small Cell Lung Cancer Using Next-Generation Sequencing

(2015) Kristin K. Deeb et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Cabozantinib for the treatment of non-small cell lung cancer with KIF5B-RET fusion. An example of swift repositioning

(2015) Minsoo Song et al.   ARCHIVES OF PHARMACAL RESEARCH

Next-generation sequencing of tyrosine kinase inhibitor-resistant non-small-cell lung cancers in patients harboring epidermal growth factor-activating mutations

(2015) Katsuhiro Masago et al.   BMC CANCER

Global cancer statistics, 2012

(2015) Lindsey A. Torre et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?

(2015) Gouji Toyokawa et al.   CANCER AND METASTASIS REVIEWS

A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance

(2015) M Dietel et al.   CANCER GENE THERAPY

Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib

(2015) J. F. Gainor et al.   CLINICAL CANCER RESEARCH

Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation

(2015) Russell W. Jenkins et al.   Clinical Lung Cancer

Diagnostic challenges in non-small-cell lung cancer: an integrated medicine approach

(2015) Ravi Salgia   Future Oncology

High-throughput diagnostic profiling of clinically actionable gene fusions in lung cancer

(2015) Nicole Pfarr et al.   GENES CHROMOSOMES & CANCER

Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update

(2015) Gregory A. Masters et al.   JOURNAL OF CLINICAL ONCOLOGY

Transformation to a squamous cell carcinoma phenotype of anEGFR-mutated NSCLC patient after treatment with an EGFR-tyrosine kinase inhibitor

(2015) Justine L Kuiper et al.   JOURNAL OF CLINICAL PATHOLOGY

Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer

(2015) Wei Sun et al.   Journal of Hematology & Oncology

Computationally unraveling how ceritinib overcomes drug-resistance mutations in ALK-rearranged lung cancer

(2015) Zhong Ni et al.   JOURNAL OF MOLECULAR MODELING

Non–Small Cell Lung Cancer, Version 6.2015

(2015) David S. Ettinger et al.   Journal of the National Comprehensive Cancer Network

BRAF Alterations as Therapeutic Targets in Non–Small-Cell Lung Cancer

(2015) Tu Nguyen-Ngoc et al.   Journal of Thoracic Oncology

Heterogeneity of Anaplastic Lymphoma Kinase Gene Rearrangement in Non–Small-Cell Lung Carcinomas: A Comparative Study Between Small Biopsy and Excision Samples

(2015) Hideyuki Abe et al.   Journal of Thoracic Oncology

Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer

(2015) Anna F. Farago et al.   Journal of Thoracic Oncology

Identification of a Novel ALK G1123S Mutation in a Patient with ALK-rearranged Non–small-cell Lung Cancer Exhibiting Resistance to Ceritinib

(2015) Gouji Toyokawa et al.   Journal of Thoracic Oncology

Targeting brain metastases in ALK-rearranged non-small-cell lung cancer

(2015) Isabella Zhang et al.   LANCET ONCOLOGY

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

(2015) James Chih-Hsin Yang et al.   LANCET ONCOLOGY

Role of circulating-tumor DNA analysis in non-small cell lung cancer

(2015) Tao Jiang et al.   LUNG CANCER

Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma

(2015) Jacques De Grève et al.   LUNG CANCER

I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib

(2015) Sai-Hong Ignatius Ou et al.   LUNG CANCER

HER2 insertion YVMA mutant lung cancer: Long natural history and response to afatinib

(2015) Bob T. Li et al.   LUNG CANCER

Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR -mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI

(2015) Samuel J. Klempner et al.   LUNG CANCER

EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291

(2015) Kenneth S. Thress et al.   LUNG CANCER

Assessment of high-sensitive methods for the detection of EGFR mutations in circulating free tumor DNA from NSCLC patients

(2015) Raffaella Pasquale et al.   PHARMACOGENOMICS

PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations

(2015) Helen Y. Zou et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors

(2015) Monika A. Davare et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Molecular and Histological Changes in Post-Treatment Biopsies of Non-Squamous Non-Small Cell Lung Cancer: A Retrospective Study

(2015) S. Vatrano et al.   Targeted Oncology

Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping

(2015) P. K. Paik et al.   Cancer Discovery

Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors

(2015) G. M. Frampton et al.   Cancer Discovery

Alectinib: a selective, next-generation ALK inhibitor for treatment of ALK-rearranged non-small-cell lung cancer

(2015) Mariacarmela Santarpia et al.   Expert Review of Respiratory Medicine

Clinical Validation of Targeted Next Generation Sequencing for Colon and Lung Cancers

(2015) Nicky D’Haene et al.   PLoS One

Efficient Genotyping of KRAS Mutant Non-Small Cell Lung Cancer Using a Multiplexed Droplet Digital PCR Approach

(2015) Alexandra Pender et al.   PLoS One

BRAF Mutant Gastrointestinal Stromal Tumor: First report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance

(2015) Gerald S. Falchook et al.   Oncotarget

Molecular pathways and therapeutic targets in lung cancer

(2015) Emma Shtivelman et al.   Oncotarget

ALKRearrangement in a Large Series of Consecutive Non–Small Cell Lung Cancers: Comparison Between a New Immunohistochemical Approach and Fluorescence In Situ Hybridization for the Screening of Patients Eligible for Crizotinib Treatment

(2014) Greta Alì et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Perfect ALKemy: Optimizing the Use of ALK-Directed Therapies in Lung Cancer

(2014) K. Politi et al.   CLINICAL CANCER RESEARCH

Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

(2014) Mark G. Kris et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

A Single-Tube Multiplexed Assay for Detecting ALK, ROS1, and RET Fusions in Lung Cancer

(2014) Maruja E. Lira et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Next-Generation Sequencing Reveals a Novel NSCLC ALK F1174V Mutation and Confirms ALK G1202R Mutation Confers High-Level Resistance to Alectinib (CH5424802/RO5424802) in ALK-Rearranged NSCLC Patients Who Progressed on Crizotinib

(2014) Sai-Hong Ignatius Ou et al.   Journal of Thoracic Oncology

Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer

(2014) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE

First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer

(2014) Benjamin J. Solomon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer

(2014) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE

U.S. Food and Drug Administration Approval Summary: Erlotinib for the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 19 Deletions or Exon 21 (L858R) Substitution Mutations

(2014) Sean Khozin et al.   ONCOLOGIST

Assessment of EGFR Mutations in Circulating Tumor Cell Preparations from NSCLC Patients by Next Generation Sequencing: Toward a Real-Time Liquid Biopsy for Treatment

(2014) Antonio Marchetti et al.   PLoS One

Genetic modifiers of EGFR dependence in non-small cell lung cancer

(2014) Tanaz Sharifnia et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Patient-derived models of acquired resistance can identify effective drug combinations for cancer

(2014) Adam S. Crystal et al.   SCIENCE

Second-Generation ALK Inhibitors: Filling the Non "MET" Gap

(2014) S. S. Ramalingam et al.   Cancer Discovery

The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer

(2014) L. Friboulet et al.   Cancer Discovery

P-loop Conformation Governed Crizotinib Resistance in G2032R-Mutated ROS1 Tyrosine Kinase: Clues from Free Energy Landscape

(2014) Huiyong Sun et al.   PLoS Computational Biology

Targeting MET Amplification as a New Oncogenic Driver

(2014) Hisato Kawakami et al.   Cancers

ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non-Small Cell Lung Cancer

(2013) J. F. Gainor et al.   CLINICAL CANCER RESEARCH

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

(2013) H. A. Yu et al.   CLINICAL CANCER RESEARCH

Combining cancer immunotherapy and targeted therapy

(2013) Antoni Ribas et al.   CURRENT OPINION IN IMMUNOLOGY

ALKin Lung Cancer: Past, Present, and Future

(2013) Alice T. Shaw et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors

(2013) Neal I. Lindeman et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Molecular Characterization of Acquired Resistance to the BRAF Inhibitor Dabrafenib in a Patient with BRAF-Mutant Non–Small-Cell Lung Cancer

(2013) Charles M. Rudin et al.   Journal of Thoracic Oncology

MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer

(2013) Bing Li et al.   LUNG CANCER

microRNA expression profiles associated with survival, disease progression, and response to gefitinib in completely resected non-small-cell lung cancer with EGFR mutation

(2013) Yi Shen et al.   MEDICAL ONCOLOGY

Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer

(2013) Aria Vaishnavi et al.   NATURE MEDICINE

Acquired Resistance to Crizotinib from a Mutation in CD74–ROS1

(2013) Mark M. Awad et al.   NEW ENGLAND JOURNAL OF MEDICINE

Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer

(2013) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE

Response to Cabozantinib in Patients with RET Fusion-Positive Lung Adenocarcinomas

(2013) Alexander Drilon et al.   Cancer Discovery

Molecular Pathology of Non–Small Cell Lung Cancer

(2012) Dara L. Aisner et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

A molecular dynamics investigation on the crizotinib resistance mechanism of C1156Y mutation in ALK

(2012) Hui-Yong Sun et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Diagnostic assays for identification of anaplastic lymphoma kinase-positive non-small cell lung cancer

(2012) Andrew J. Weickhardt et al.   CANCER

SnapShot: Non-Small Cell Lung Cancer

(2012) Rebecca S. Heist et al.   CANCER CELL

Mechanisms of Resistance to Crizotinib in Patients withALKGene Rearranged Non–Small Cell Lung Cancer

(2012) Robert C. Doebele et al.   CLINICAL CANCER RESEARCH

Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 (HER2) Tyrosine Kinase Mutations in Lung Adenocarcinomas

(2012) M. E. Arcila et al.   CLINICAL CANCER RESEARCH

Strategies for Overcoming EGFR Resistance in the Treatment of Advanced-Stage NSCLC

(2012) Christine M. Lovly et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

ROS1 as a ‘druggable’ receptor tyrosine kinase: lessons learned from inhibiting the ALK pathway

(2012) Sai-Hong Ignatius Ou et al.   Expert Review of Anticancer Therapy

RETFusions Define a Unique Molecular and Clinicopathologic Subtype of Non–Small-Cell Lung Cancer

(2012) Rui Wang et al.   JOURNAL OF CLINICAL ONCOLOGY

EGFRmutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples

(2012) Gillian Ellison et al.   JOURNAL OF CLINICAL PATHOLOGY

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

(2012) Rafael Rosell et al.   LANCET ONCOLOGY

ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors

(2012) G. Hatzivassiliou et al.   MOLECULAR CANCER THERAPEUTICS

Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies

(2012) Doron Lipson et al.   NATURE MEDICINE

KIF5B-RET fusions in lung adenocarcinoma

(2012) Takashi Kohno et al.   NATURE MEDICINE

RET, ROS1 and ALK fusions in lung cancer

(2012) Kengo Takeuchi et al.   NATURE MEDICINE

Anaplastic lymphoma kinase (ALK): Structure, oncogenic activation, and pharmacological inhibition

(2012) Robert Roskoski   PHARMACOLOGICAL RESEARCH

Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1

(2012) K. Ohashi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers

(2012) R. Katayama et al.   Science Translational Medicine

Melanoma whole-exome sequencing identifies V600E B-RAF amplification-mediated acquired B-RAF inhibitor resistance

(2012) Hubing Shi et al.   Nature Communications

Reactivation of ERK Signaling Causes Resistance to EGFR Kinase Inhibitors

(2012) Dalia Ercan et al.   Cancer Discovery

A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors

(2011) T. Sasaki et al.   CANCER RESEARCH

Identification of the MEK1(F129L) Activating Mutation as a Potential Mechanism of Acquired Resistance to MEK Inhibition in Human Cancers Carrying the B-RafV600E Mutation

(2011) H. Wang et al.   CANCER RESEARCH

A Drug Resistance Screen Using a Selective MET Inhibitor Reveals a Spectrum of Mutations That Partially Overlap with Activating Mutations Found in Cancer Patients

(2011) R. Tiedt et al.   CANCER RESEARCH

Crizotinib-Resistant Mutants of EML4-ALK Identified Through an Accelerated Mutagenesis Screen

(2011) Sen Zhang et al.   Chemical Biology & Drug Design

New Strategies in Overcoming Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer

(2011) G. R. Oxnard et al.   CLINICAL CANCER RESEARCH

Screening for activating EGFR mutations in surgically resected nonsmall cell lung cancer

(2011) K. B. Sriram et al.   EUROPEAN RESPIRATORY JOURNAL

Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling

(2011) Nikhil Wagle et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Harboring BRAF Mutations

(2011) Antonio Marchetti et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical Characteristics of Patients With Lung Adenocarcinomas HarboringBRAFMutations

(2011) Paul K. Paik et al.   JOURNAL OF CLINICAL ONCOLOGY

EGFRMutation Is a Better Predictor of Response to Tyrosine Kinase Inhibitors in Non–Small Cell Lung Carcinoma Than FISH, CISH, and Immunohistochemistry

(2010) Lynette M. Sholl et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

MET and KRAS Gene Amplification Mediates Acquired Resistance to MET Tyrosine Kinase Inhibitors

(2010) V. Cepero et al.   CANCER RESEARCH

Small-Cell Carcinoma With an Epidermal Growth Factor Receptor Mutation in a Never-Smoker With Gefitinib-Responsive Adenocarcinoma of the Lung

(2010) Naheed Alam et al.   Clinical Lung Cancer

Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine

(2010) Dora Dias-Santagata et al.   EMBO Molecular Medicine

Lung Adenocarcinoma From East Asian Never-Smokers Is a Disease Largely Defined by Targetable Oncogenic Mutant Kinases

(2010) Yihua Sun et al.   JOURNAL OF CLINICAL ONCOLOGY

EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors

(2010) Young Lim Choi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

(2010) Eunice L. Kwak et al.   NEW ENGLAND JOURNAL OF MEDICINE

IncreasedMETGene Copy Number Negatively Affects Survival of Surgically Resected Non–Small-Cell Lung Cancer Patients

(2009) Federico Cappuzzo et al.   JOURNAL OF CLINICAL ONCOLOGY

MET Gene Copy Number in Non-small Cell Lung Cancer: Molecular Analysis in a Targeted Tyrosine Kinase Inhibitor Naïve Cohort

(2009) Michèle Beau-Faller et al.   Journal of Thoracic Oncology

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Paxillin Is a Target for Somatic Mutations in Lung Cancer: Implications for Cell Growth and Invasion

(2008) R. Jagadeeswaran et al.   CANCER RESEARCH

Novel MEK1 Mutation Identified by Mutational Analysis of Epidermal Growth Factor Receptor Signaling Pathway Genes in Lung Adenocarcinoma

(2008) J. L. Marks et al.   CANCER RESEARCH

Frequency and Distinctive Spectrum of KRAS Mutations in Never Smokers with Lung Adenocarcinoma

(2008) G. J. Riely et al.   CLINICAL CANCER RESEARCH

Biomarkers of Response to Epidermal Growth Factor Receptor Inhibitors in Non–Small-Cell Lung Cancer Working Group: Standardization for Use in the Clinical Trial Setting

(2008) David A. Eberhard et al.   JOURNAL OF CLINICAL ONCOLOGY